TY - JOUR
T1 - Severe COVID-19 infection in a kidney transplant recipient treated with lopinavir/ritonavir, hydroxychloroquine and dexamethasone
AU - Suryantoro, Satriyo Dwi
AU - Thaha, Mochammad
AU - Pranawa,
AU - Santoso, Djoko
AU - Mardiana, Nunuk
AU - Widodo,
AU - Aditiawardana,
AU - Tjempakasari, Artaria
AU - Ardhany, Ardityo Rahmat
AU - Pramudya, Dana
AU - Hertanto, Decsa Medika
AU - Febriane, Evy
AU - Meryana,
AU - Angela, Maria
AU - Muliono, Ari Christy
AU - Tanuwidjaja, Handoko
AU - Setiawan, Philia
AU - Sugiarto, David
N1 - Publisher Copyright:
© 2021 Suryantoro et al.
PY - 2021/9
Y1 - 2021/9
N2 - Severe COVID-19 infection management for a recipient of kidney transplant has debatable prognosis and treatment. We described the case of a COVID-19 infected 70 year old female, previously had renal transplantation in 2017. The patient took immunosuppressive agents as routine drugs for transplant recipient status and received lopinavir/ritonavir, hydroxychloroquine, and dexamethasone daily at the hospitalization. Specific question arises about renal transplant recipients being infected by COVID-19 - whether the infection will get worse compared to those without immunosuppresive agent. In this case, author decided to stop the immunosuppressive agent followed administration of combination lopinavir/ritonavir, hydroxychloroquine, and dexamethasone that gives a good clinical impact change to patient's condition after once getting worsened and mechanically ventilated. Nevertheless, the assessment of risk and benefit in continuing immunosuppressive drugs is concurrently essential due to the prevention of transplant rejection.
AB - Severe COVID-19 infection management for a recipient of kidney transplant has debatable prognosis and treatment. We described the case of a COVID-19 infected 70 year old female, previously had renal transplantation in 2017. The patient took immunosuppressive agents as routine drugs for transplant recipient status and received lopinavir/ritonavir, hydroxychloroquine, and dexamethasone daily at the hospitalization. Specific question arises about renal transplant recipients being infected by COVID-19 - whether the infection will get worse compared to those without immunosuppresive agent. In this case, author decided to stop the immunosuppressive agent followed administration of combination lopinavir/ritonavir, hydroxychloroquine, and dexamethasone that gives a good clinical impact change to patient's condition after once getting worsened and mechanically ventilated. Nevertheless, the assessment of risk and benefit in continuing immunosuppressive drugs is concurrently essential due to the prevention of transplant rejection.
KW - COVID-19
KW - Hydroxycholorquin
KW - Immunosupressive drugs
KW - Kidney transplant
KW - Lopinavir/ritonavir
UR - http://www.scopus.com/inward/record.url?scp=85118309976&partnerID=8YFLogxK
U2 - 10.3855/jidc.14952
DO - 10.3855/jidc.14952
M3 - Article
AN - SCOPUS:85118309976
SN - 2036-6590
VL - 15
SP - 1257
EP - 1262
JO - Journal of Infection in Developing Countries
JF - Journal of Infection in Developing Countries
IS - 9
ER -
